Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL169983 | 0.96 | MAPT (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL17697673 | 0.93 | ZDHHC7 (0.33) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL973726 | 0.88 | MAPT (0.43) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL2731548 | 0.88 | MAPT (0.43) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL8673442 | 0.88 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL4704955 | 0.87 | MAPT (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL3204051 | 0.86 | MEN1 (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL7691355 | 0.85 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL3838857 | 0.85 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL326451 | 0.84 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118265737-A | Triarylamine high molecular weight compound and organic electroluminescent element | 保土谷化学工业株式会社 | 2024-06-28 | — | — | CN | disclosed |
| US-11999818-B2 | High molecular weight triarylamine compound comprising terphenyl structure in molecular main chain and organic electroluminescent element comprising said high molecular weight compound | HODOGAYA CHEMICAL CO., LTD. (JP) | 2024-06-04 | — | — | US | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| CN-117362601-A | High molecular weight compound and organic electroluminescent element using same | 保土谷化学工业株式会社 | 2024-01-09 | — | — | CN | disclosed |
| CN-117295779-A | Triarylamine high molecular weight compound and organic electroluminescent element comprising same | 保土谷化学工业株式会社 | 2023-12-26 | — | — | CN | disclosed |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20230389408-A1 | METAL COMPLEX AND USE THEREOF | SICHUAN AG-RAY NEW MATERIALS CO., LTD (CN) | 2023-11-30 | — | — | US | disclosed |
| CN-114426563-B | Metal complex and application thereof | 四川阿格瑞新材料有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| EP-0672686-A1 | GANGLIOSIDE GM3 DERIVATIVE HAVING FLUORINATED CERAMIDE MOIETY | DAIKIN INDUSTRIES, LIMITED (JP) | 1995-09-20 | — | — | EP | disclosed |
| EP-0670315-A1 | Triazole oxime derivatives having antimycotic acitivity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| US-5442060-A | Treating hyperlipemia, atherosclerosis | MITSUBISHI KASEI CORPORATION (JP) | 1995-08-15 | — | — | US | disclosed |
| US-5433887-A | Liquid crystal compounds | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1995-07-18 | — | — | US | disclosed |
| US-5352820-A | Expedient route to aryl propenoic esters | AMERICAN CYANAMID COMPANY | 1994-10-04 | — | — | US | disclosed |
| EP-0591830-A1 | Carboxamide and urea derivatives having ACAT-inhibiting activityM | Mitsubishi Chemical Corporation (JP) | 1994-04-13 | — | — | EP | disclosed |
| US-5248810-A | Insecticides, acaricides | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-09-28 | — | — | US | disclosed |
| US-5082856-A | Hyperlipemia, arteriosclerosis | MITSUBISHI KASEI CORPORATION (JP) | 1992-01-21 | — | — | US | disclosed |
| EP-0432861-A1 | Halogenated olefines, process for the preparation thereof and their use as pesticides | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-06-19 | — | — | EP | disclosed |
| EP-0347902-A2 | Pyrrolecarboxylic acid derivatives | Mitsubishi Chemical Corporation (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | MEN1 3985/4885MAPT 1809/4885KMT2A 1904/4885 |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, FH | MEN1 114/4885MAPT 825/4885KMT2A 1485/4885 |
| US-20230389408-A1 | METAL COMPLEX AND USE THEREOF | CYBA, AP1M1, AP3M1 | MEN1 623/4885MAPT 860/4885KMT2A 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.